Mark Litwin

Mark S. Litwin is professor of Health Policy & Management, Urology, and Nursing and serves as chair of the Department of Urology in the School of Medicine. In addition to teaching and mentoring students in HPM, he is a practicing urologic oncologist. Dr. Litwin is a translational population scientist who teaches and conducts research in quality of care, health-related quality of life, medical outcomes, medical decision-making, costs and resource utilization, patient preferences, and health care access. He published the first validated quality-of-life instrument to track outcomes in men with prostate cancer and has been an international leader in this area. His research has been funded by the NIDDK, NCI, Department of Defense, American Cancer Society, California Department of Public Health, Movember Foundation, and other organizations. He has been continuously NIH-funded since 1997. His current projects include a $1149 million award to provide prostate cancer care to low-income, uninsured men in California, established in 2001. For 14 years he led Urologic Diseases in America, a $24 million epidemiologic study funded by the NIDDK. He is PI of an innovative T32 program to train fellows in patient-centered outcomes research in urologic and gynecologic oncology. His former fellows hold positions at academic institutions throughout the world. Dr. Litwin received the AUA Gold Cystoscope for his foundational work in establishing the discipline of urological health services research. He also received the AUA Foundation’s Distinguished Mentor Award, the AUA Distinguished Service Award, the Barringer Medal from the American Association of Genitourinary Surgeons, and the Joseph A. Smith Mentorship Award from the Society of Urologic Oncology. He teaches in the Fielding Schools of Public Health and the David Geffen School of Medicine at UCLA.


  • MD, Emory University, Atlanta, GA
  • MPH, University of California, Los Angeles, CA
  • BS, Duke University, Durham, NC

Areas of Interest

  • Quality of Care
  • Medical Outcomes
  • Health-Related Quality of Life
  • Resource Use
  • Urological Diseases
  • Prostate Cancer